Finoriq research workspace
Kiniksa Pharmaceuticals International, plc (KNSA) Institutional Holdings & 13F Ownership
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops. Review KNSA institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Company
- Kiniksa Pharmaceuticals International, plc (KNSA)
- Ticker
- KNSA
- Market Cap
- $4.8B
- Latest Price
- $62.69
- Industry
- Biotech & Pharma
Kiniksa Pharmaceuticals International, plc (KNSA) Top Institutional Holders
Top current 13F holders indexed for Kiniksa Pharmaceuticals International, plc (KNSA). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Ken FisherCIK 0000850529 | $20.7M | 0.01% | Filing2026-05-05 |
| 2 | Joel GreenblattCIK 0001510387 | $364,688 | 0.0% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.